Affordable Access

A novel translocation, t(9;17)(q34;q23), in aggressive childhood lymphoblastic lymphoma.

Authors
  • Kaneko, Y1
  • Frizzera, G
  • Maseki, N
  • Sakurai, M
  • Komada, Y
  • Sakurai, M
  • Hiyoshi, Y
  • Nakadate, H
  • Takeda, T
  • 1 Department of Laboratory Medicine, Saitama Cancer Center, Japan.
Type
Published Article
Journal
Leukemia
Publication Date
November 1988
Volume
2
Issue
11
Pages
745–748
Identifiers
PMID: 3054349
Source
Medline
License
Unknown

Abstract

In a chromosome study of childhood lymphoblastic lymphoma, we found a novel translocation, t(9;17)(q34;q23), in three patients. They presented with mediastinal mass and no bone marrow involvement. Despite intensive chemotherapy, one patient had no response, the other two relapsed after a brief remission, and all progressed to death. The 9;17 translocation may have a clinical implication for lymphoblastic lymphoma patients in predicting a poor prognosis. Since, in addition to our cases, involvement of the 9q34 breakpoint, together with 2q33, 14q11, or 7q34, has been reported in the literature in four lymphoblastic lymphoma patients, a gene located in 9q34 and referred to as tcl-3 may participate in the genesis of the T cell malignancies carrying these translocations. Furthermore, as is the case in other lymphomas, the reciprocal breakpoint, 17q23, might be the site of a yet unidentified T cell function gene.

Report this publication

Statistics

Seen <100 times